RxDoctor Payments Data

Amy Clinton, NP

Adult Health · Spartanburg, SCNPI 1992962427

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,447 of the $6,827 with a category attached, or 79.8%. 44 manufacturers reported payments, led by Novartis at 26.7% of the total. Among adult health clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,827in general payments, 2019–2025

Across 276 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Merck$419
  • E.r. Squibb & Sons, L.L.C.$399
  • Eisai Inc.$376
  • Daiichi Sankyo Inc.$316
  • Johnson & Johnson$304
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,44780%
  • Education$1001%
  • Other$1,28019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,827 in reported general payments places this provider in the 90th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$46,693
Medicare patients
108
Services billed
4,738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$10,290
Ibandronate Sodium57$1,483
Letrozole65$1,449
Anastrozole37$815
Tamoxifen Citrate29$669
Venlafaxine Hcl ErVenlafaxine Hcl12$262
Nystatin14$229
Gabapentin12$145
Alendronate Sodium13$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$226$10,29011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 adult health providers in South Carolina.

Other adult health in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →